China’s state council demands raised quality for ‘essential drugs’
This article was originally published in Scrip
Executive Summary
Officials at the highest level of China’s government have said that the quality of medicines on China’s essential drugs list must be raised to international standards, a move that challenges the existing essential drugs scheme in the country.
You may also be interested in...
FDA nod for first 'made in China' MAb
China is known for a global supplier of active pharmaceutical ingredients, but with continuous investment in advanced facilities and talents, it is likely to be a global supplier of biological therapies. The US approval of a 'made in China' monoclonal antibody for use in clinical trials marks a milestone in China's journey.
Fosun licenses novel TB treatment for China
Shanghai-based, Hong Kong and Shanghai listed Fosun Pharmaceutical has been busy adding foreign assets under its belt.
China's state council demands raised quality for "essential drugs"
Officials at the highest level of China's government have said that the quality of medicines on China's essential drugs list must be raised to international standards, a move that challenges the existing essential drugs scheme in the country1.